From June 16 to 18, the 24th World API China Exhibition (CPHI China 2026) was held at the Shanghai New International Expo Center. Biocompounds Pharmaceutical Inc. participated together with its two factories—Anhui Bocompounds Pharmaceutical Co., Ltd and Anhui Biocompounds Chemicals Co., Ltd

This edition of the exhibition brought together more than 3,700 renowned exhibitors from home and abroad and attracted over 110,000 professional visitors from more than 180 countries and regions worldwide—making it the largest and most internationalized full-industry-chain pharmaceutical event in Asia. At the show, the Beika team prominently promoted its core products and new-product pipeline including Methyldopa, Fuluolashen, and Azilsartan Potassium, and systematically introduced the company's product portfolio and factory production capacity in core areas such as cardiovascular and anti-infective drugs. As a mature product cultivated for many years, Methyldopa—with its stable quality and continuous process optimization—has earned the recognition and long-term cooperation of multiple international customers. Fuluolashen and Azilsartan Potassium, as newly prioritized products, are seeing rising market demand and drew the attention and inquiries of many domestic and overseas customers during the exhibition. In addition, the finished-drug export segment of Jianfeng Pharmaceutical was promoted at the show, demonstrating an integrated service capability from API to finished formulation and opening a window for the group's international expansion of its formulation business. During the exhibition, the Beika team reached preliminary intent with multiple customers on new-product cooperation, custom manufacturing, and long-term strategic partnerships.